Stephanie Hemmingson1, Kelly Perlewitz2, Megan Holtorf2, Ian Tagge1, William Woodward1, Christopher Ryan2, Charles Springer1, Wei Huang1
1Advanced Imaging Research Center, Oregon Health & Science University, Portland, OR, United States; 2Medicine, Oregon Health & Science University, Portland, OR, United States
The Ktrans DCE-MRI parametric biomarker was tested on the first three soft-tissue sarcoma patients undergoing a phase I trial of antiangiogenic potentiatiated preoperative chemoradiotherapy. DCE-MRI data were acquired before therapy, after two weeks of antiangiogenic therapy only, and after eight more weeks of antiangiogenic therapy plus chemoradiotherapy. The % changes in tumor ROI and histogram median Ktrans values after two weeks provided superior early prediction of therapy pathologic response compared to those in tumor size and other kinetic parameters. Median Ktrans value after two weeks exhibited a linear relationship with the % necrosis of surgical specimens after ten weeks.